CorMedix
CRMD
65 hedge funds and large institutions have $47M invested in CorMedix in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 20 increasing their positions, 18 reducing their positions, and 10 closing their positions.
50% more capital invested
Capital invested by funds: $31.3M → $47M (+$15.7M)
11% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 18
0.8% more ownership
Funds ownership: 26.73% → 27.53% (+0.8%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
11% less funds holding
Funds holding: 73 → 65 (-8)
68% less call options, than puts
Call options by funds: $448K | Put options by funds: $1.4M
70% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$473K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$407K |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$390K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$354K |
| 5 |
D.E. Shaw & Co
New York
|
+$331K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
E
Ergoteles
New York
|
-$450K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$211K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$136K |
| 4 |
State Street
Boston,
Massachusetts
|
-$96.6K |
| 5 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$88.4K |
CRMD Hedge Fund Activity: Q4 2022 in Review
65 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in CorMedix (CRMD) for Q4 2022, worth a combined $47M — up 50% from $31.3M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of CRMD and 3 opened new positions — a net loss of 7 holders — while 18 trimmed existing stakes and 20 added.
The largest buyer was Citadel Advisors, adding an estimated $473K. The largest seller was Ergoteles, exiting entirely with an estimated $450K sold.
- 65 institutional investors held CorMedix (CRMD) as of Q4 2022, down from 73 in Q3 2022.
- Funds reported $47M of CorMedix stock for Q4 2022, up 50% quarter-over-quarter.
- 3 funds opened new CorMedix positions in Q4 2022 and 10 closed out, a net change of -7 holders.
- The largest CorMedix buyer in Q4 2022 was Citadel Advisors, an estimated $473K added.
- The largest CorMedix seller in Q4 2022 was Ergoteles, an estimated $450K sold.
Based on aggregated 13F filings for Q4 2022.